{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for sulfisoxazole root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
US Approved Rx
(2022)
Source:
NDA215866
(2022)
Source URL:
First approved in 2022
Source:
NDA215866
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2003)
Source:
NDA021481
(2003)
Source URL:
First approved in 2003
Source:
NDA021481
Source URL:
Class:
PROTEIN
Conditions:
Enfuvirtide is a linear 36-amino acid synthetic peptide that inhibits the fusion of HIV-1 with CD4 cells. Enfuvirtide works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected. Enfuvirtide interferes with the entry of HIV-1 into cells by inhibiting fusion of viral and cellular membranes. Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. Enfuvirtide is indicated for the treatment of HIV-1 infection, in combination therapy with other antiretrovirals, in patients where all other treatments have failed. Common adverse drug reactions associated with enfuvirtide therapy include: injection site reactions (pain, hardening of skin, erythema, nodules, cysts, itch; experienced by nearly all patients, particularly in the first week), peripheral neuropathy, insomnia, depression, cough, dyspnoea, anorexia, arthralgia, infections (including bacterial pneumonia) and/or eosinophilia.
Status:
Investigational
Source:
INN:peceleganan [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pobrolitide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:pegtarviliase [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:pegzilarginase [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03226444: Phase 1/Phase 2 Interventional Completed Primary Sjögren Syndrome
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:mipeginterferon alfa-2b [INN]
Source URL:
Class:
PROTEIN